drugset
drugset / Trial / NCT07640438

Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ

NCT07640438 ↗

Phase 1 Recruiting 104 enrolled First Affiliated Hospital of Zhejiang University Beijing Hikinge Pharmaceutical Technology Co., Ltd. · collabBiyopharma Co., LTD，Hangzhou， China · collabSDM Bioservices Inc. · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

The objective of this clinical trial is to evaluate the safety and tolerability of BY002 in healthy subjects. Investigators will compare BY002 to a placebo (a pharmacologically inactive substance) to assess the safety and tolerability of BY002 in healthy subjects. Participants will undergo: 1. Single/multiple subcutaneous (SC) administrations of BY002/placebo 2. A 7-day safety follow-up period following the last dose

Timeline

Start
2026-06-01
Primary completion
2026-11-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BY002 Unknown 10 mg Subcutaneous
Subject BY002 Unknown 25 mg Subcutaneous
Subject BY002 Unknown 50 mg Subcutaneous
Subject BY002 Unknown 100 mg Subcutaneous
Subject BY002 Unknown 150 mg Subcutaneous
Subject BY002 Unknown 200 mg Subcutaneous

Indications

No indication recorded.